CloneID: A1431
Antigen Long Description: The original antibody was isolated from an anti-NoV GII.4c IgG serum antibody repertoire generated from three donors that experienced a significant increase in GII.4 titer after immunization with the bivalent GII.4c + GI.1 VLP vaccine.
Buffer Composition: PBS with 0.02% Proclin 300.
Chimeric Use Statement: This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format for improved compatibility with existing reagents assays and techniques.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: S5YAA0
Specificity Statement: This antibody recognizes conserved residues distal to the HBGA binding pocket but accessible on the assembled VLP. It binds each P domain monomer at a cleft between the P1 and P2 subdomains. Norovirus (NoVs) is one of the main pathogens causing sporadic cases and large outbreaks of acute gastroenteritis, and norovirus can infect people of all ages.
Application Notes (Clone): This antibody showed broad blockade towards to all known historical GII.4 strains from 1987 onwards and neutralized the pandemic GII.P16-GII.4 Sydney strain. This antibody is also capable of blocking the VLP binding to histoblood group antigens (HBGAs). Structure revealed conserved epitopes, which were occluded on the virion or partially exposed, allowing for broad blockade with neutralizing activity. The HBGA blocking assay was used to characterize A1431 against a panel of pandemic norovirus GII.4 strains. ELISA was used to determine the binding specificity of the antibody for GII.4c VLP (PMID: 31216462).
English
Deutsch
